Inclusion Criteria:

          1. Signed Informed consent

          2. Classical IPSS intermediate 1 or low myelodysplastic syndrome associated with at least
             one poor prognosis feature:

               1. Intermediate or higher risk revised IPSS

               2. RBC transfusion dependent anemia and failure to 2 or more lines or therapy
                  (including EPO, Lenalidomide or demethylating agent…)

               3. thrombocytopenia < 20 G/L requiring transfusion

               4. neutropenia < 0.5 G/L associated with severe infection (defined as requiring
                  hospitalization)

          3. Patient aged ≥ 18 and < 70 years For young patients, 18-45 years, Fanconi disease and
             dyskeratosis should be ruled out

          4. Patient for whom a transplantation from a matched donor, (8/8 (HLA A, B, C, DRB1)
             identical at molecular level)unrelated donor or matched sibling), is considered
             irrespective of donor availability

          5. Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale (At time
             of screening)

          6. Negative pregnancy and adequate contraception (including in male patients wishing to
             father), if relevant.

          7. Wash-out of at least 30 days since a previous treatment with Vidaza, Lenalidomide, EPO
             or any other treatment inducing cytopenias.

        Exclusion Criteria:

          1. MDS classified according to classical IPSS as intermediate 2 or High risk

          2. Transformation in Acute myeloid Leukemia (AML)

          3. Severe active infection or any other uncontrolled severe condition.

          4. Organ dysfunctions including the following

               -  Hepatic : total bilirubin > 2 times upper limit of normal (ULN) (except moderate
                  unconjugated hyperbilirubinemia due to intra medullary hemolysis or Gilbert
                  syndrome) , alanine transaminase (ALT) and aspartate transaminase (AST) > 3xULN

               -  Symptomatic respiratory chronic failure

               -  Symptomatic cardiac failure

               -  Renal clearance < 60ml/min

          5. Prior malignancy (except in situ cervix carcinoma, limited basal cell carcinoma, or
             other tumors if not active during the last 3 years)

          6. MDS with the following causal germline disease : Fanconi anemia, GATA2 related
             syndromes and telomere disorders